understand
etiolog
pathogenesi
consequ
acut
exacerb
chronic
obstruct
pulmonari
diseas
copd
increas
substanti
last
decad
sever
new
line
evid
demonstr
bacteri
isol
sputum
acut
exacerb
mani
instanc
refl
ect
causeeffect
relationship
placebocontrol
antibiot
trial
exacerb
copd
demonstr
signifi
cant
clinic
benefi
ts
antibiot
treatment
moder
sever
episod
howev
multitud
antibiot
comparison
trial
choic
antibiot
appear
affect
clinic
outcom
explain
sever
methodolog
limit
trial
recent
comparison
trial
nontradit
endpoint
shown
differ
among
antibiot
treatment
exacerb
copd
observ
studi
examin
clinic
outcom
exacerb
repeatedli
demonstr
certain
clinic
characterist
associ
treatment
failur
earli
relaps
optim
antibiot
select
exacerb
therefor
incorpor
quantifi
risk
poor
outcom
exacerb
choos
antibiot
differ
low
risk
high
risk
patient
reserv
broader
spectrum
drug
high
risk
patient
though
improv
outcom
exacerb
antibiot
choic
base
risk
stratifi
cation
yet
demonstr
prospect
control
trial
approach
take
account
concern
diseas
heterogen
antibiot
resist
judici
antibiot
use
exacerb
chronic
obstruct
pulmonari
diseas
copd
fourth
lead
caus
death
unit
state
lead
caus
worldwid
estim
would
becom
lead
caus
death
us
worldwid
affect
million
peopl
us
half
undiagnos
account
million
offi
ce
visit
million
emerg
room
visit
hospit
annual
estim
direct
cost
billion
nhlbi
copd
chronic
diseas
mostli
manag
outpati
basi
part
natur
histori
diseas
intermitt
acut
episod
increas
respiratori
symptom
wors
pulmonari
function
may
accompani
fever
constitut
symptom
character
acut
exacerb
exacerb
major
driver
offi
ce
visit
hospit
therefor
cost
care
copd
advanc
diseas
also
frequent
caus
death
diseas
burrow
earl
calverley
et
al
frequenc
exacerb
vari
wide
patient
gener
correl
sever
durat
underli
copd
besid
mortal
exacerb
copd
associ
import
decrement
healthrel
qualiti
life
seemung
et
al
spencer
et
al
though
acut
symptom
tend
subsid
cours
week
qualiti
life
take
sever
month
recov
furthermor
recoveri
delay
exacerb
siddiqi
sethi
recur
recov
period
spencer
jone
contrari
previou
studi
recent
data
shown
frequenc
exacerb
associ
acceler
long
term
declin
lung
function
measur
forc
expiratori
volum
second
fev
shown
mild
diseas
lung
health
studi
everi
lower
respiratori
tract
ill
associ
addit
loss
ml
fev
kanner
et
al
patient
moder
sever
copd
experi
frequent
exacerb
also
experi
declin
fev
mlyr
contrast
declin
mlyear
among
patient
infrequ
exacerb
donaldson
et
al
clear
exacerb
major
contributor
morbid
cost
mortal
associ
copd
substanti
progress
also
made
understand
etiolog
pathogenesi
contrast
clinic
studi
adequ
design
qualiti
help
us
determin
optim
manag
approach
exacerb
still
rel
among
therapeut
option
treatment
acut
exacerb
antibiot
though
wide
use
treatment
exacerb
use
still
debat
whether
antibiot
choic
import
controversi
hirschmann
murphi
et
al
optim
approach
antibiot
treatment
exacerb
reli
upon
accur
diagnosi
includ
judici
applic
diagnost
test
need
follow
determin
sever
exacerb
probabl
bacteri
whether
antibiot
indic
decis
made
antibiot
inde
indic
risk
stratifi
cation
approach
allow
us
choos
appropri
antibiot
accur
diagnosi
reli
clear
defi
nition
univers
agre
upon
includ
object
measur
unfortun
situat
acut
exacerb
copd
imprecis
variabl
defi
nition
absenc
object
measur
rodriguezroisin
two
wide
use
defi
nition
exacerb
anthonisen
defi
nition
base
presenc
one
three
cardin
symptom
includ
increas
new
onset
dyspnea
sputum
product
sputum
purul
anthonisen
et
al
case
one
cardin
symptom
present
one
support
symptom
sign
requir
make
diagnosi
includ
upper
respiratori
tract
infect
past
fi
day
wheez
cough
fever
without
obviou
sourc
increas
respiratori
rate
heart
rate
baselin
though
simpl
clinic
use
defi
nition
narrow
scope
sever
import
symptom
exacerb
chest
congest
chest
tight
fatigu
sleep
disturb
includ
wider
defi
nition
consensu
panel
defi
ne
exacerb
acut
sustain
worsen
patient
condit
stabl
state
beyond
day
day
variabl
requir
addit
treatment
rodriguezroisin
defi
nition
though
inclus
specifi
c
regard
natur
durat
symptom
also
miss
defi
nition
clinic
exclus
entiti
could
present
similar
manner
pneumonia
congest
heart
failur
upper
respiratori
infect
noncompli
medic
etc
older
research
fi
eld
exclud
entiti
defi
nition
confound
research
fi
nding
clinic
approach
exacerb
clinic
entiti
distinct
etiolog
pathogenesi
treatment
therefor
differenti
diagnosi
exacerb
rather
includ
defi
nition
clinic
studi
suspect
exacerb
patient
copd
report
minor
increas
new
onset
two
major
increas
new
onset
one
follow
respiratori
symptom
dyspnea
cough
sputum
product
sputum
tenac
sputum
purul
increas
symptom
least
hour
durat
greater
intens
normal
day
day
variabl
defi
nition
requir
symptom
least
hr
even
hr
durat
furthermor
describ
clinic
evalu
exclud
clinic
entiti
could
present
similar
manner
sever
exacerb
complic
concept
constitut
least
two
factor
sever
underli
copd
acut
chang
induc
exacerb
therefor
patient
got
sever
underli
copd
may
signifi
cant
clinic
consequ
rel
small
chang
baselin
state
patient
mild
copd
may
abl
toler
much
larger
chang
symptom
lung
function
differ
notion
exacerb
sever
use
ideal
chang
lung
function
use
defi
ne
sever
exacerb
howev
lung
function
diffi
cult
measur
exacerb
often
chang
exacerb
magnitud
day
day
variabl
measur
sever
also
measur
site
care
hospit
exacerb
regard
sever
outpati
exacerb
regard
moder
self
medic
exacerb
mild
gold
classifi
cation
prone
error
site
care
depend
differ
among
countri
health
care
system
threshold
admiss
patient
physician
prefer
etc
anoth
suggest
measur
sever
exacerb
intens
treatment
recommend
treatment
bronchodil
indic
mild
exacerb
treatment
antibiot
steroid
addit
bronchodil
regard
indic
moder
sever
exacerb
approach
beset
problem
prefer
practic
approach
one
wide
use
determin
sever
known
anthonisen
classifi
cation
anthonisen
et
al
classifi
cation
reli
number
cardin
symptom
presenc
support
symptom
shown
tabl
interestingli
classifi
cation
design
classifi
cation
sever
exacerb
becom
time
determin
sever
rel
simpl
correl
benefi
antibiot
benefi
seen
type
exacerb
howev
limit
anthonisen
sever
classifi
cation
valid
object
measur
sever
associ
benefi
antibiot
reproduc
studi
anoth
limit
lack
gradat
sever
within
symptom
exacerb
mild
dyspnea
mild
increas
sputum
would
regard
sever
classifi
cation
one
mark
increas
symptom
evid
need
better
defi
nition
object
measur
sever
exacerb
biomark
repres
object
measur
potenti
could
either
defi
ne
exacerb
determin
etiolog
determin
sever
recent
studi
hurst
et
al
plasma
biomark
patient
exacerb
none
alon
combin
adequ
defi
ne
exacerb
hurst
et
al
anoth
studi
multipl
serum
biomark
hospit
patient
exacerb
reduct
correl
decreas
dyspnea
recoveri
exacerb
decreas
tumor
necrosi
factor
proport
recoveri
fev
pintoplata
et
al
sputum
free
neutrophil
elastas
activ
shown
correl
clinic
sever
exacerb
assess
clinic
score
base
symptom
sign
develop
patient
report
outcom
biomark
provid
us
better
defi
nition
object
measur
sever
exacerb
futur
emerg
concept
increas
airway
infl
ammat
baselin
level
characterist
copd
central
pathogenesi
acut
exacerb
support
sever
recent
studi
sethi
measur
airway
infl
ammat
induc
expector
sputum
bronchoalveolar
lavag
bronchial
biopsi
reveal
increas
airway
infl
ammat
inde
present
acut
exacerb
resolv
treatment
neutrophil
eosinophil
infl
ammat
describ
former
associ
bacteri
etiolog
latter
viral
infect
stimulu
acut
increas
airway
infl
ammat
could
lead
increas
bronchial
tone
edema
bronchial
wall
mucu
product
alreadi
diseas
lung
process
could
worsen
ventilationperfus
mismatch
expiratori
fl
ow
limit
correspond
clinic
manifest
dyspnea
cough
increas
sputum
product
tenac
purul
along
worsen
ga
exchang
cardin
manifest
exacerb
increas
plasma
fi
brinogen
interleukin
creactiv
protein
crp
consist
heighten
state
system
infl
ammat
describ
exacerb
dev
et
al
wedzicha
et
al
mediat
like
caus
system
manifest
exacerb
includ
fatigu
instanc
fever
varieti
noninfecti
infecti
stimuli
induc
acut
increas
airway
infl
ammat
copd
therebi
caus
manifest
exacerb
epidemiolog
studi
demonstr
increas
respiratori
symptom
respiratori
mortal
among
patient
copd
period
increas
air
pollut
sunyer
et
al
garciaaymerich
et
al
sunyer
et
al
inde
environment
pollut
particul
matter
nonparticul
gase
ozon
nitrogen
dioxid
sulfur
dioxid
capabl
induc
infl
ammat
vitro
vivo
devalia
et
al
ohtoshi
et
al
rudel
et
al
infecti
agent
includ
bacteria
virus
atyp
pathogen
implic
caus
acut
exacerb
discuss
greater
detail
sethi
list
potenti
pathogen
copd
exacerb
includ
typic
respiratori
bacteri
pathogen
respiratori
virus
atyp
bacteria
tabl
among
typic
bacteria
nontyp
haemophilu
infl
uenza
nthi
common
role
copd
best
understood
eldika
sethi
among
virus
rhinoviru
respiratori
syncyti
viru
rsv
receiv
consider
attent
recent
year
seemung
et
al
falsey
et
al
certain
share
characterist
pathogen
provid
clue
predilect
caus
infect
copd
nthi
streptococcu
pneumonia
moraxella
catarrhali
predomin
bacteri
caus
two
common
respiratori
mucos
infect
acut
otiti
media
children
acut
sinus
children
adult
mucos
infect
relat
anatom
abnorm
impair
drainag
secret
anteced
viral
infect
defect
innat
adapt
immun
predispos
factor
like
exist
copd
three
pathogen
exclus
human
pathogen
transmit
among
individu
healthi
host
presenc
confi
ned
upper
airway
caus
clinic
manifest
like
acquisit
pathogen
patient
copd
compromis
lung
defens
allow
establish
infect
lower
respiratori
tract
without
overt
clinic
manifest
respiratori
virus
implic
copd
abl
caus
acut
tracheobronchi
infect
healthi
host
clinic
refer
acut
bronchiti
set
copd
diminish
respiratori
reserv
acut
bronchiti
profound
manifest
seriou
clinic
consequ
understand
acut
exacerb
pathogenesi
especi
relat
bacteri
infect
seen
signifi
cant
progress
last
year
host
pathogen
factor
involv
develop
acut
bacteri
exacerb
figur
acquisit
strain
bacteri
pathogen
new
host
environ
appear
primari
event
put
patient
copd
risk
exacerb
variat
among
strain
speci
surfac
antigen
structur
seen
nthi
pneumonia
catarrhali
allow
newli
acquir
strain
escap
preexist
host
immun
respons
develop
follow
prior
exposur
strain
speci
bacteria
strain
therefor
prolifer
lower
airway
induc
acut
infl
ammat
airway
virul
strain
yet
unidentifi
ed
host
factor
may
determin
acut
infl
ammatori
respons
pathogen
reach
threshold
caus
symptom
present
exacerb
chin
et
al
mani
instanc
adapt
immun
respons
result
develop
mucos
system
antibodi
pathogen
murphi
et
al
immun
respons
combin
appropri
antibiot
abl
elimin
control
prolifer
infect
bacteria
howev
antigen
variabl
among
strain
bacteri
speci
antibodi
develop
infect
strain
usual
strainspecifi
c
provid
protect
host
antigen
distinct
strain
speci
allow
process
recurr
bacteri
infect
exacerb
patient
pathogenesi
acut
viral
exacerb
less
well
understood
howev
appear
similar
bacteri
infect
common
caus
exacerb
rhinoviru
demonstr
consider
antigen
variat
among
serotyp
allow
recurr
infect
infl
uenza
viru
demonstr
drift
antigen
makeup
major
surfac
protein
therebi
lead
recurr
infect
vitro
virus
damag
airway
epithelium
stimul
muscarin
receptor
induc
eosinophil
infl
ux
stimul
secret
rant
johnston
et
al
proinfl
ammatori
action
could
potenti
induc
pathophysiolog
manifest
character
acut
exacerb
viral
agent
infect
lower
airway
patient
copd
pathogenesi
exacerb
atyp
bacteri
infect
poorli
understood
tradit
aim
treatment
exacerb
recoveri
baselin
clinic
statu
prevent
complic
though
goal
undoubtedli
import
sever
new
observ
question
adequaci
goal
includ
new
understand
import
exacerb
cours
copd
role
infect
exacerb
high
rate
relaps
adequ
initi
clinic
respons
role
play
chronic
infect
pathogenesi
copd
draw
analog
confi
ning
goal
treatment
copd
exacerb
short
term
resolut
symptom
would
equival
treat
acut
myocardi
infarct
aim
resolut
chest
pain
sever
import
goal
treatment
clinic
biolog
consid
tabl
instanc
clinic
success
treatment
exacerb
defi
ned
resolut
symptom
baselin
improv
symptom
degre
treatment
requir
opinion
treat
physician
symptom
inde
correl
exagger
airway
system
infl
ammat
accept
clinic
improv
rather
clinic
resolut
import
implic
clinic
improv
may
refl
ect
inadequ
treatment
permit
infl
ammatori
process
underli
exacerb
persist
prolong
period
time
therefor
clinic
resolut
symptom
baselin
may
actual
repres
optim
outcom
import
clinic
goal
treatment
includ
delay
next
exacerb
prevent
earli
relaps
rapid
resolut
symptom
anzueto
et
al
aaron
et
al
lengthen
interexacerb
interv
prevent
earli
relaps
increasingli
recogn
import
clinic
goal
treatment
ultim
translat
decreas
frequenc
exacerb
major
focu
copd
treatment
though
patient
physician
would
accept
faster
recoveri
baselin
desir
goal
treatment
accept
goal
hamper
lack
well
valid
instrument
reliabl
measur
rate
resolut
exacerb
nonclin
goal
treatment
either
still
infanc
case
bacteriolog
erad
use
clinic
studi
satisfi
regulatori
requir
approv
new
antibiot
exacerb
infl
ammatori
event
would
logic
resolut
infl
ammat
baselin
import
goal
treatment
similarli
exacerb
mani
instanc
induc
infect
therefor
erad
offend
infecti
pathogen
goal
treatment
practic
applic
biolog
goal
treatment
exacerb
await
develop
simpl
rapid
reliabl
measur
infl
ammat
infect
exacerb
requir
multiprong
approach
util
sever
therapeut
modal
simultan
either
reliev
symptom
treat
underli
caus
provid
support
till
recoveri
occur
sethi
gold
therapi
includ
bronchodil
corticosteroid
antimicrobi
mucolyt
expector
sever
case
oxygen
supplement
mechan
ventil
acut
respiratori
failur
subsequ
discuss
focu
role
antibiot
treatment
acut
exacerb
role
choic
antibiot
treatment
exacerb
matter
controversi
recommend
antibiot
use
among
publish
guidelin
often
inconsist
time
vagu
bach
et
al
balter
et
al
celli
macne
gold
pauciti
welldesign
larg
random
control
trial
fi
eld
upon
base
solid
recommend
undoubtedli
contribut
state
affair
sethi
recent
well
design
placebo
control
antibiot
comparison
trial
report
addit
epidemiolog
studi
consist
identifi
ed
certain
risk
factor
presenc
patient
acut
exacerb
predict
failur
treatment
earli
relaps
increas
realiz
heterogen
copd
exacerb
use
antibiot
episod
may
provid
optim
outcom
like
proport
treatment
failur
exacerb
relat
ineffect
antibiot
treatment
therefor
patient
risk
poor
outcom
logic
candid
aggress
initi
antibiot
treatment
expect
approach
would
improv
overal
outcom
exacerb
risk
stratifi
cation
approach
also
advoc
communityacquir
infect
pneumonia
acut
sinus
mandel
et
al
sinu
allergi
health
though
improv
outcom
risk
stratifi
cation
yet
demonstr
prospect
control
trial
approach
take
account
concern
diseas
heterogen
antibiot
resist
judici
antibiot
use
exacerb
contrast
magnitud
problem
exacerb
copd
result
signifi
cant
antibiot
consumpt
hand
placebocontrol
trial
diseas
two
metaanalys
placebocontrol
trial
exacerb
publish
fi
rst
analysi
publish
nine
trial
met
qualiti
criteria
small
signifi
cant
benefi
cial
effect
antibiot
placebo
acut
exacerb
demonstr
saint
et
al
second
analysi
trial
includ
much
larger
benefi
cial
effect
mortal
prevent
clinic
failur
demonstr
especi
moder
sever
exacerb
ram
et
al
number
need
treat
sever
exacerb
hospit
patient
prevent
one
death
three
patient
number
need
treat
prevent
one
clinic
failur
six
patient
diarrhea
frequent
relat
advers
effect
one
episod
per
seven
patient
treat
antibiot
treatment
benefi
cial
resolv
sputum
purul
howev
benefi
ts
lung
function
ga
exchang
observ
differ
result
two
metaanalys
explain
larg
part
addit
later
analysi
studi
perform
tunisia
publish
studi
patient
exacerb
sever
underli
copd
requir
ventil
support
intens
care
unit
randomli
assign
receiv
ofl
oxacin
placebo
doubl
blind
manner
nouira
et
al
system
corticosteroid
administ
potenti
respiratori
bacteri
pathogen
isol
tracheobronchi
aspir
patient
ofl
oxacin
result
dramat
benefi
compar
placebo
reduc
mortal
need
addit
antibiot
respect
tabl
anoth
interest
studi
though
includ
either
metaanalysi
publish
italian
allegra
colleagu
addit
analysi
later
publish
english
trial
amoxicillinclavun
compar
placebo
exacerb
patient
vari
sever
underli
copd
allegra
et
al
uniqu
featur
studi
measur
primari
outcom
day
instead
tradit
week
clinic
success
includ
resolut
improv
signifi
cantli
better
antibiot
seen
patient
compar
placebo
arm
greater
benefi
antibiot
compar
placebo
seen
increas
sever
underli
copd
result
metaanalys
studi
along
previou
classic
larg
placebocontrol
trial
conduct
anthonisen
colleagu
show
antibiot
benefi
cial
treatment
moder
sever
exacerb
anthonisen
et
al
allegra
et
al
nouira
et
al
ram
et
al
furthermor
benefi
antibiot
mark
earli
cours
exacerb
suggest
antibiot
hasten
resolut
symptom
allegra
et
al
howev
still
import
unresolv
question
regard
role
antibiot
exacerb
benefi
antibiot
mild
exacerb
unproven
warrant
placebo
control
trial
whether
antibiot
benefi
treatment
exacerb
short
cours
system
corticosteroid
coadminist
still
studi
larg
well
design
trial
one
would
suspect
would
addit
benefi
ts
treatment
use
either
treatment
alon
woodbak
et
al
ram
et
al
though
one
quit
confi
dent
antibiot
use
moder
sever
exacerb
copd
consider
discuss
antibiot
choic
especi
initi
empir
therapi
bach
et
al
balter
et
al
celli
macne
sethi
murphi
gold
exacerb
nowaday
treat
without
obtain
sputum
bacteriolog
initi
empir
choic
often
becom
choic
made
antibiot
use
exacerb
result
antibiot
comparison
trial
guid
recommend
appropri
empir
antibiot
exacerb
howev
though
larg
number
trial
conduct
vast
major
antibiot
choic
appear
affect
clinic
outcom
differ
bacteriolog
erad
rate
seen
appar
dissoci
clinic
bacteriolog
outcom
obaji
sethi
contrari
expect
antibiot
better
vitro
vivo
antimicrobi
effi
caci
better
pharmacodynam
pharmacokinet
characterist
show
superior
clinic
outcom
paradox
like
relat
sever
shortcom
design
trial
tabl
sethi
mani
defi
cienci
explain
fact
trial
perform
regulatori
approv
drug
therefor
design
demonstr
noninferior
rather
differ
two
antibiot
two
recent
antibiot
comparison
trial
design
show
differ
among
antibiot
measur
unconvent
clinic
relev
endpoint
globe
gemifl
oxacin
long
term
outcom
bronchiti
exacerb
trial
prospect
doubl
blind
random
trial
compar
fl
uoroquinolon
gemifl
oxacin
macrolid
clarithromycin
wilson
et
al
end
therapi
longterm
outcom
assess
made
convent
day
day
time
interv
assess
line
antibiot
comparison
trial
statist
signific
differ
two
arm
clinic
outcom
clinic
success
rate
gemifl
oxacin
clarithromycin
respect
bacteriolog
success
undetect
bia
use
concurr
therapi
measur
erad
presum
erad
signifi
cantli
higher
gemifl
oxacin
compar
clarithromycin
patient
success
clinic
outcom
day
offer
enrol
follow
period
total
week
observ
time
period
primari
outcom
rate
repeat
exacerb
hospit
respiratori
diseas
healthrel
qualiti
life
measur
gemifl
oxacin
associ
signifi
cantli
lower
rate
repeat
exacerb
gemifl
oxacintr
patient
remain
exacerb
free
week
comparison
clarithromycin
arm
rel
risk
reduct
recurr
exacerb
rate
hospit
respiratori
tract
ill
week
also
lower
gemifl
oxacintr
patient
clarithromycin
treat
patient
vs
p
wilson
et
al
patient
recurr
exacerb
week
period
lesser
improv
healthrel
qualiti
life
compar
remain
free
recurr
spencer
jone
trial
clearli
demonstr
limit
convent
mediumterm
clinic
outcom
demonstr
differ
among
antibiot
exacerb
week
follow
period
institut
signifi
cant
differ
clinic
relev
outcom
recurr
exacerb
respiratori
relat
hospit
would
miss
anoth
recent
landmark
antibiot
comparison
trial
mosaic
trial
trial
larg
studi
patient
random
fl
uoroquinolon
moxifl
oxacin
standard
therapi
could
one
follow
amoxicillin
cefuroxim
clarithromycin
wilson
et
al
trial
sever
uniqu
design
featur
relat
observ
made
studi
rel
larg
number
patient
enrol
addit
patient
enrol
stabl
establish
baselin
comparison
reliabl
distinguish
clinic
improv
resolut
follow
treatment
substanti
proport
patient
enrol
one
risk
factor
would
predispos
poor
outcom
discuss
patient
follow
month
random
provid
estim
recurr
exacerb
interestingli
line
usual
antibiot
comparison
trial
moxifloxacin
standard
therapi
equival
vs
clinic
success
resolut
improv
compar
day
end
therapi
howev
moxifl
oxacin
therapi
associ
superior
clinic
cure
rate
defi
ned
resolut
symptom
baselin
rather
simpli
improv
standard
therapi
vs
well
superior
bacteriolog
respons
vs
addit
priori
unconvent
endpoint
examin
moxifl
oxacin
associ
fewer
requir
addit
antibiot
therapi
vs
extend
time
next
exacerb
versu
day
wilson
et
al
composit
endpoint
clinic
failur
requir
addit
antibiot
recurr
exacerb
demonstr
clear
differ
two
arm
studi
moxifl
oxacin
superior
standard
therapi
month
follow
figur
convent
outcom
clinic
success
would
measur
sole
studi
signifi
cant
differ
two
arm
would
discov
result
globe
mosaic
trial
demonstr
vitro
microbiolog
superior
fl
uoroquinolon
translat
greater
vivo
effect
treat
patient
acut
exacerb
differ
among
antibiot
often
percept
standard
regulatori
endpoint
clinic
success
day
end
therapi
howev
differ
among
antibiot
percept
clinic
relev
endpoint
speed
resolut
clinic
cure
need
addit
antimicrobi
time
next
exacerb
consid
wilson
et
al
wilson
et
al
base
mosaic
globe
studi
result
would
tempt
prescrib
fl
uoroquinolon
moder
sever
exacerb
howev
clear
strategi
though
like
success
shortterm
would
foster
antimicrobi
resist
valuabl
antibiot
long
term
therefor
would
judici
make
effort
identifi
patient
like
benefi
antibiot
sever
studi
demonstr
certain
patient
characterist
anted
onset
exacerb
impact
outcom
exacerb
ball
et
al
adam
et
al
dewan
et
al
groenewegen
et
al
wilson
et
al
interestingli
sever
characterist
relev
outcom
one
studi
risk
factor
poor
outcom
consid
decis
regard
choic
antibiot
treat
exacerb
theoret
patient
greater
risk
poor
outcom
would
greatest
benefi
earli
aggress
antibiot
therapi
fl
uoroquinolon
patient
consequ
treatment
antibiot
ineffect
pathogen
caus
exacerb
like
signifi
cant
clinic
failur
hospit
earli
recurr
like
among
risk
factor
poor
outcom
identifi
ed
variou
studi
increas
age
sever
underli
airway
obstruct
presenc
comorbid
ill
especi
cardiac
diseas
histori
recurr
exacerb
use
home
oxygen
use
chronic
steroid
hypercapnia
acut
bronchodil
use
ball
et
al
adam
et
al
dewan
et
al
groenewegen
et
al
wilson
et
al
risk
factor
like
highli
correl
home
oxygen
use
hypercapnia
chronic
steroid
use
like
refl
ect
increas
sever
underli
copd
acut
bronchodil
use
could
relat
sever
underli
copd
refl
ect
wheezi
phenotyp
exacerb
may
less
respons
antibiot
treatment
mani
risk
factor
discuss
continu
sever
howev
certain
threshold
defi
ned
studi
clinic
use
predict
poor
outcom
includ
age
yr
fev
less
exacerb
previou
month
addit
risk
factor
describ
experi
respiratori
infect
tell
us
recent
antibiot
use
within
past
month
place
patient
high
risk
group
harbor
antibiot
resist
pathogen
therefor
poor
outcom
best
describ
pneumonia
among
patient
commun
acquir
pneumococc
pneumonia
recent
also
describ
pathogen
among
patient
copd
vanderkooi
et
al
sethi
et
al
whether
select
antibiot
resist
strain
occur
among
nthi
catarrhali
antibiot
exposur
known
risk
stratifi
cation
approach
advoc
sever
expert
initi
empir
antibiot
treatment
acut
exacerb
base
risk
factor
discuss
vitro
vivo
effi
caci
antibiot
current
treatment
algorithm
similar
other
advoc
shown
figur
balter
et
al
sethi
murphi
gold
initi
step
algorithm
determin
sever
exacerb
base
discuss
use
anthonisen
criteria
singl
cardin
symptom
exacerb
defi
ned
mild
presenc
cardin
symptom
defi
ne
moder
sever
exacerb
mild
exacerb
manag
symptomat
treatment
antibiot
prescrib
unless
symptom
progress
moder
sever
exacerb
import
step
differenti
uncompl
simpl
patient
complic
patient
uncompl
patient
risk
factor
poor
outcom
complic
patient
one
follow
risk
factor
poor
outcom
age
fev
comorbid
cardiac
diseas
exacerb
previou
month
balter
et
al
sethi
murphi
gold
antibiot
choic
patient
uncompl
copd
includ
advanc
macrolid
azithromycin
clarithromycin
ketolid
telithromycin
cephalosporin
cefuroxim
cefpodoxim
cefdinir
doxycyclin
trimethoprimsulfamethoxazol
amoxicillin
appropri
choic
consider
incid
product
among
nthi
catarrhali
two
major
pathogen
exacerb
complic
patient
antibiot
choic
includ
respiratori
fl
uoroquinolon
moxifl
oxacin
gemifl
oxacin
levofl
oxacin
amoxicillinclavulan
choos
antibiot
consider
also
import
patient
exposur
antibiot
within
past
month
elucid
exposur
antibiot
confi
ned
prescrib
respiratori
infect
includ
antibiot
prescrib
indic
antibiot
chosen
differ
class
agent
one
prescrib
within
past
month
exampl
exposur
macrolid
past
three
month
lead
use
cephalosporin
uncompl
patient
similarli
prior
use
fl
uoroquinolon
complic
patient
lead
use
amoxicillinclavulan
subgroup
complic
patient
risk
infect
pseudomona
aeruginosa
enterobacteriacea
document
infect
pathogen
soler
et
al
patient
usual
sever
underli
copd
fev
develop
bronchiectasi
hospit
often
requir
intens
care
recent
hospit
receiv
multipl
cours
antibiot
patient
empir
treatment
ciprofl
oxacin
appropri
howev
emerg
resist
among
p
aeruginosa
fl
uoroquinolon
may
compromis
effi
caci
therefor
subgroup
patient
sputum
tracheobronchi
aspir
intub
cultur
obtain
allow
adjust
antibiot
base
vitro
suscept
pathogen
isol
howev
combin
parenter
antibiot
therapi
p
aeruginosa
set
never
systemat
examin
unproven
benefi
patient
reassess
hr
time
frame
clinic
improv
appar
patient
fail
initi
empir
antimicrobi
therapi
would
appropri
reexamin
patient
confi
rm
diagnosi
consid
sputum
studi
ascertain
resist
diffi
cult
treat
pathogen
treat
altern
agent
better
vitro
microbiolog
effi
caci
purul
sputum
ie
amount
yellow
green
pigment
sputum
relat
presenc
myeloperoxidas
product
neutrophil
degranul
neutrophil
degranul
associ
bacteri
infect
purul
sputum
exacerb
shown
marker
bacteri
infect
defi
ned
quantit
cultur
sputum
well
bronchoscop
protect
specimen
brush
specimen
stockley
et
al
soler
et
al
presenc
sputum
purul
advoc
sole
determin
antibiot
treatment
exacerb
howev
accuraci
reproduc
indic
bacteri
infect
limit
like
even
clinic
practic
research
studi
stockley
et
al
soler
et
al
sputum
purul
incorpor
anthonisen
criteria
use
conjunct
symptom
measur
risk
stratifi
cation
antibiot
treatment
exacerb
figur
biomark
bacteri
infect
repres
anoth
approach
antibiot
use
exacerb
copd
best
studi
biomark
bacteri
infect
serum
procalcitonin
level
recent
studi
patient
hospit
exacerb
antibiot
treatment
prescrib
procalcitonin
level
certain
threshold
investig
show
differ
outcom
spite
reduct
antibiot
use
procalcitonin
guidanc
stolz
et
al
though
fi
nding
studi
interest
approach
need
valid
multicent
trial
vari
popul
martinez
curti
furthermor
need
test
outpati
exacerb
major
exacerb
treat
patient
close
supervis
support
care
less
rigor
minor
patient
receiv
fl
uoroquinolon
studi
antibiot
choic
complic
patient
per
risk
stratifi
cation
discuss
therefor
reason
specul
withhold
antibiot
may
effect
fi
rst
place
like
much
impact
studi
short
term
goal
well
biolog
goal
bacteri
erad
infl
ammat
reduct
discuss
also
record
import
consider
antibiot
prescrib
safeti
toler
agent
drug
interact
fi
nalli
cost
treatment
cost
antibiot
howev
interpret
isol
shown
elegantli
miravittl
colleagu
exacerb
initi
empir
treatment
fail
ten
time
costli
clinic
success
miravitl
et
al
fact
overal
cost
care
could
reduc
half
reduct
clinic
failur
rate
clinic
failur
rate
like
reduc
antibiot
choic
appropri
logic
discuss
